Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novartis and Ionis have experienced a significant setback regarding a drug designed to target lipoprotein(a), commonly known as Lp(a). The failure of this specific trial has created immediate uncertainty regarding the efficacy of the drug candidate and the broader strategy for addressing this particular heart-related risk factor. Coverage from BioPharma Dive emphasizes that this outcome is spurring wider questions about an entire emerging class of heart medicines. The focus is not only on the specific failure of the Novartis and Ionis collaboration but on whether other drugs targeting Lp(a) will face similar challenges. Meanwhile, Barron's reports on the financial implications for Novartis, specifically questioning whether the company's shares can be lifted by other catalysts.
The reporting highlights a tension between the failure of this cardiovascular trial and the potential for other assets, such as rare-disease treatments, to offset the negative impact on the company's market valuation. To understand the significance of this event, it is necessary to recognize that Lp(a) is a target for a new category of pharmaceutical interventions. Because this represents an emerging class of medicines, the Phase 3 trial was seen as a critical bellwether for the viability of the approach. A failure at this late stage of clinical testing suggests that targeting Lp(a) may be more complex than previously anticipated by researchers and investors in the biopharmaceutical sector. Moving forward, observers will be monitoring how Novartis manages its portfolio following this stumble.
Barron's suggests that the focus may shift toward the company's rare-disease treatment pipeline to see if those developments can provide a necessary boost to share prices. Additionally, the pharmaceutical industry will likely scrutinize other companies developing heart medicines within this same emerging class to see if the Novartis and Ionis failure indicates a systemic issue with Lp(a) targeting. The specific impact on the partnership between Novartis and Ionis remains a key point of interest as the market digests the trial results.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (81% supported) Updated 70d ago.
Quick answers
Which companies were involved in the drug trial?
The trial involved Novartis and Ionis.
What was the specific goal of the drug?
The drug was designed to lower cardiovascular risk by targeting lipoprotein(a), or Lp(a).
What stage of testing did the drug fail?
The drug failed during a closely watched Phase 3 trial.
Coverage (2)
- Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines BioPharma Dive · 74d ago
- A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares? Barron's · 74d ago
Topics
Related trends
Experts spell out what heart health means for women of all ages
New joint heart health guidance from the American Heart Association and three other medical groups urges cardiovascular screening for women at every life stage.
Column | Your stroke risk is 72 percent higher during these 3 hours of the day
Multiple outlets report stroke risk spikes 72 percent higher during a specific three-hour morning window, citing new medical research.
Could This Everyday Drink Help Your Heart? A Study of Nearly 500,000 People Offers New Evidence
New research involving nearly 500,000 people examines how drinking tea may protect vascular health and lower heart disease risk.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
'Good' Body Fat Is Linked to Fewer Anxiety And Depression Diagnoses
A widely prescribed blood pressure drug increased calorie-burning brown fat in mice, according to a recent study.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.